ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0962

Variability in Racial Disparities in Pregnancy Outcomes in Women with SLE by Diagnosis Algorithm
Abstract Number: 1825

Vascular Calcifications Adjacent to the Involved Joint of Patients Diagnosed with Calcium Pyrophosphate Crystal Arthritis – a Retrospective Observational Study
Abstract Number: 1608

Vascular Effect of Treat to Target in Early Rheumatoid Arthritis Patients – A 5-year Prospective Study
Abstract Number: 1574

Vasculitides as Medication-Associated Adverse Events Based on a National Database Reporting System
Abstract Number: 1251

Venous Halo Sign Detected with Superb Microvascular Imaging in Behçet Syndrome
Abstract Number: 0557

VEXAS Syndrome Is Characterized by Blood and Tissues Inflammasome Pathway Activation and Monocyte Dysregulation
Abstract Number: 1029

Virtual Assessment in Axial Spondyloarthritis: Validation of Video Observation of Spinal Metrology
Abstract Number: 0749

Virtual Care in Rheumatology Ambulatory Clinics During the COVID-19 Pandemic: Patient/Family and Healthcare Provider Perspectives and Experiences
Abstract Number: 0205

Virtually Training Peer Coaches to Use Motivational Interviewing Skills: Processes from a Rheumatoid Arthritis Intervention Training Program
Abstract Number: 1059

Vision Transformer Assisting Rheumatologists in Screening for Capillaroscopy Changes in Systemic Sclerosis: An Artificial Intelligence Solution
Abstract Number: 0924

Vitamin B12 Status and Hyperhomocysteinemia in Patients with Rheumatoid Arthritis Treated with Methotrexate and Folic Acid
Abstract Number: 1200

Vitamin D and Marine n-3 Fatty Acid Supplementation for Prevention of Autoimmune Disease in the VITAL Randomized Controlled Trial: Outcomes over 7 Years
Abstract Number: 1653

Voclosporin for Lupus Nephritis: Assessment of Long-Term Safety and Efficacy Including Renal Outcome over Three Years of Treatment in the Phase 3 AURORA 1 and AURORA 2 Studies
Abstract Number: 0357

Voclosporin Is Effective in Achieving Proteinuria Treatment Targets in Lupus Nephritis Defined by EULAR/ERA Recommendations
Abstract Number: 1573

Von – Willebrand Factor, a Possible Marker for Disease Activity in Vasculitis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].